As of September 30, 2024, Seres had $66.8 million in cash and cash equivalents. Based on existing cash, projected installment payments to be received from Nestle Health Science in 2025, transaction-related obligations and current operating plans, the Company expects to fund operations into the fourth quarter of 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MCRB:
- Seres Therapeutics Inc. (MCRB) Q3 Earnings Cheat Sheet
- Seres Therapeutics downgraded to Underweight from Neutral at JPMorgan
- Seres Therapeutics rumor highlighted in Betaville blog
- Seres Therapeutics files to sell 14.29M shares of common stock for holders
- Seres Therapeutics Streamlines Focus with VOWST Sale to Nestlé